Clinical Trial Detail

NCT ID NCT02504489
Title Plinabulin (P) + Docetaxel (D) vs D as 2nd-Line Chemo in Patients With Advanced NSCLC With at Least 1 Large Lung Lesion
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors BeyondSpring Pharmaceuticals Inc.
Indications

non-small cell lung carcinoma

Therapies

Docetaxel

Docetaxel + Plinabulin

Age Groups: adult

Additional content available in CKB BOOST